This action might not be possible to undo. Are you sure you want to continue?
February 12, 2004
Recent NIDA Staff Appointments/Changes
Richard A. Millstein, J.D.
Acting Deputy Director NIH John E. Fogarty International Center for Advanced Study in the Health Sciences
Recent NIDA Staff Appointments/Changes Timothy P. Condon, Ph.D.
Deputy Director, NIDA Director, OSPC
Director’s Report to the National Advisory Council on Drug Abuse
What’s New at NIH? Budget Update Recent NIDA Activities Science Highlights FY 2004 and Beyond
What’s New at NIH?
Lung and Blood Institute Anthony Fauci – National Institute of Allergy and Infectious Diseases .NIH Central Steering Committee Rotating Members (three year terms): • • • • • • • • • • Francis Collins Richard Hodes Stephen Katz Donald Lindberg Stephen Straus Larry Tabak Nora Volkow Genome Research Institute Aging Arthritis Musculoskeletal & Skin Diseases National Library of Medicine Complementary & Alternative Medicine Dental & Craniofacial Research NIDA Permanent Members (three largest institutes): Andrew von Eschenbach – National Cancer Institute Barbara Albin – National Heart.
Promote innovation and risk-taking in intramural research. high Meet New Challenges potential payoff research. Enhance and increase trans-NIH strategic planning Organizational Change to 7. Health: 4.Report by National Research Council and IoM 2. Enhancing the Vitality of the National Institutes of and funding. . 8. Create a Director’s Special Projects Program to support high risk. Create a public process for considering proposed changes in the number of NIH institutes or centers.
THE NIH ROADMAP An Agency-Wide Effort To Identify the Critical Roadblocks and Knowledge Gaps That Constrain Rapid Advances in Biomedical Research Progress • Molecular Libraries and Imaging • Research Teams of the Future • High-Risk Research • Private-Public Partnerships • Re-engineering the Clinical Research Enterprise .
Condon named NIDA’s representative for the Roadmap Program officers have contacted potential grantees to encourage them to submit grants for Roadmap RFAs Created a page on NIDA website that highlights opportunities from the roadmap relevant to NIH grantees Periodic staff meetings with NIDA Director to review progress and plan strategies .What Has NIDA Done to Ensure Participation of Substance Abuse Researchers on the NIH Roadmap? • • • • Dr.
Kington. NIH Deputy Director.D.. NIH Blue Ribbon Panel established to review current NIH Ethics policies NIH Ethics Advisory Committee (NEAC) established (composed of members of the NIH community) .. M. Ph. appointed as Deputy Ethics Counselor (DEC) for the NIH and the Office of the Director.Ethics Issues at NIH Concern by congress that there may be conflict between the role of NIH directors and of NIH scientists and private partnerships New Initiatives to Strenthen the NIH Ethics Program: • • • Raynard S.D.
Financial Maagement and EEO Harmonization of and accountability for achieving both corporate NIH objectives and IC-specific objectives – Looking at “Dual Reporting” for senior IC staff FTE Ceiling imposed to limit the number of NIH employees at each institute. Grants Management.NIH Consolidation and Centralization Activities (occurring through several approaches) Outsourcing studies: NIH “competes” against outside contractors Extramural Support was studied last year 656 FTEs now in ICs (22 in NIDA) will be centralized into a new NIH Office the “MEO” – Most Efficient Organization -. NIH Administrative Restructuring Plan – ARAC (Administrative Restructuring and Advisory Committee) Consolidation of functions in several areas including: Personnel. NIDA’s is 373 in FY04 . 2004. Acquisitions.Implementation Date: April 1. Budget. Information Technology. Facilities.
Budget Update .
328 $315.060 $1.979 $312.732 $1.019.808 $677.945 $960.787 $990. P.B.979 $990.0% 2005 2005 P.NIDA BUDGET (Thousands) (Thousands) 2003 2003 Actual Actual NonAIDS NonAIDS AIDS AIDS TOTAL TOTAL Increase Over Increase Over Prior Year Prior Year $659.9% +2.B.514 $960.431 $301.514 $301.060 +2.0% +3.431 $659.808 $312.945 +8.9% .2% +8.2% 2004 2004 Estimate Estimate $677.019. $703.787 +3.328 $703.732 $315.
Recent NIDA Activities .
New NIDA PAs and RFAs Prevention Research (Children and Adolescents) Novel Approaches to Phenotyping Drug Abuse (RFA) Behavioral and Cognitive Processes in Adolescent Drug Abuse (RFA) Animal Models of Adolescent Drug Abuse (RFA) Prevention Research for the Transition to Adulthood (RFA) Consequences of Marijuana Use on the Developing Brain (RFA) Treatment Interventions Medications Development for Cannabis-Related Disorders (RFA) .
New NIDA PAs and RFAs HIV/HCV Drug Abuse Aspects of HIV/AIDS and Other Infections (PA) HIV/AIDS and Other Infections Among Drug Users in the Criminal Justice System (RFA) Targeted Integrative Research in Drug Abuse and HIV/AIDS in Pregnancy (RFA) Training Research Education Grants in Drug Abuse and Addiction (PA) .
8 Million) Focus predominantly on: CO-MORBIDITY Mental illness Alcoholism HIV .PAs and RFA With Other NIH Components 8 New PAs and 4 New RFAs (Totaling $9.
Addiction Technology Transfer Center (ATTC) Blending Initiative NIDA/SAMHSA BLENDING TEAMS Members of CSAT’s ATTC Network + NIDA Researchers Training materials and products to help program managers. administrators and policy makers use Addiction Severity Index (ASI) results for management and program planning decisions Buprenorphine awareness training and materials for non-physicians in the drug abuse and addiction field .
Highlights of Recent Meetings and Events .
. M. Director. 393 ~ 2003 ~ 576 of 16. NIDA NIDA-Sponsored Mini-Convention Growth in Drug Abuse-Related Presentations ~ 2002 ~ 471 of 13. Volkow.155 .D.Society for Neuroscience Annual Meeting Opening Plenary Lecture THE ADDICTED HUMAN BRAIN Nora D.
We Recently Released Our New Website for Teens! .
drug. coalition partners and corporate sponsors Baltimore MD December 31... . .and smoke-free community event) Co-sponsored by NIDA in collaboration with the Maryland Chapter of the American Academy of Pediatrics. 2003 . 2003 Tent at New Year’s Eve Spectacular (widely attended alcohol.NIDA’s Primary Healthcare Outreach Initiative . Educational Seminar for Primary Health Care Providers Co-sponsored by NIDA and the Sheppard Pratt Health System Sheppard Pratt Conference Center Baltimore MD December 17.
Science Highlights .
3 19.2 18 17 16 17.Percent of Students Reporting Past Month Use of Any Illicit Drug GREAT NEWS!! 20 19 18.4 2001 2002 2003 Monitoring the Future Study 2003 11% Decline 2001 to 2003 .
0 4.2 3.0 0.5 7.0 10.0 2. 2003.0 8.5 2.8 10.0 8th Grade 10th Grade 12th Grade Percent Oxycontin Vicodin Source: Monitoring the Future Study.0 6.6 1.Percent of Students Reporting Abuse of Pain Killers in Past 12 Months in 2003 WORRISOME NEWS 12. .7 4.
2002 NSDUH .Numbers of New Abusers of Prescription Drugs: 1965-2001 Source: SAMHSA.
5 3 2.4 million Millions of Americans 2.5 0 4.2 million Stimulants Sedatives Pain Relievers Millions of Americans Abuse Prescription Drugs .5 1 0.5 4 3.Use of Prescription Drugs for Non-Medical Purposes 2002 National Survey on Drug Use and Health 4.5 2 1.2 million 1.
Why Has the Abuse of Prescription Drugs Increased? Increasing numbers of prescriptions (greater availability) Attention by the media and advertising (television and newspaper) Easier access (e. internet availability) Improper knowledge and monitoring (adverse effects go unrecognized) .g.
As Prescriptions Increase Emergency Room Visits For Non-Medical Abuse Have Also Increased Number of Prescriptions (in 1000s) 80000 70000 60000 50000 40000 30000 20000 10000 0 24000 18000 12000 6000 0 Hydrocodone prescriptions emergency ED Mentions Oxycodone prescriptions emergency 1996 1998 1994 1995 1997 1999 2000 Source: SAMHSA. 2002 2001 . DAWN.
Increased Media Attention .
Availability on the Internet Delivered in the Privacy of your Home “Some reasons why you should consider using this pharmacy” No prescription required! .
e lethal overdose with pain killers. psychosis with stimulant medications Misuse in elderly populations who are particularly sensitive to adverse medical reactions Increase use by adolescents of drugs that may have long term effects in brain development .Other Reasons for Concern These drugs can have serious medical consequences i.
How Does NIDA’s Science Help Fight Prescription Drug Abuse? .
hence formulations that can interfere with the drug effects if injected would decrease its diversion and abuse .Continue Research on Prescription Drugs and on Treatment and Prevention When analgesics are injected they are much more addictive than when taken orally.
What could have accounted for this reduction? Example for Marihuana: As Perceived Risk Increases Use Decreases % Reporting Use % Reporting Harmfulness 60 50 40 30 20 10 0 '75 '77 '79 '81 '83 '85 '87 '89 '91 '93 '95 '97 '99 '01 '03 Education of patients. pharmacists and the public Year . physicians.
Development of Alternative Medications with no Drug Abuse Potential .
FY 2005 and Beyond .
Risky Behavior and HIV on Adolescent Brain Drug Abuse Prevention and Treatment in Primary Care System Neurobiological Processes Underlying Co-morbidity • • .NIDA FY 2005 Initiatives • Prevention Research (Children and Adolescents) • • • • • Treatment Interventions • Pharmacogenetics and Medications Development Training • Using Science to Improve Providers’ Knowledge and Skills • Gene/Environment Interactions Drug Exposure and the Developing Prenatal Brain The Effects of Drugs of Abuse Across the Lifespan Impact of Drugs.
Systems and Translational Research Approaches in Addiction • Infrastructure Development and the Creation of Translational Research Centers DRUGS OF ABUSE social behavior neuronal circuits protein expression genome .
Brain. Behavior & Health Roadmap .
Brain. Behavior & Health Initiative Mission To develop the knowledge and the technology necessary for understanding how the human brain • works and molds human behavior. • how genes and environmental factors mold its development and function • how it changes throughout the lifespan This knowledge will help to better understand brain diseases including ADDICTION. and to develop strategies to promote optimal health .
. institutes and agencies.FIRST MILESTONE Create a matrix that will Catalog ongoing projects that pertain to a brain/behavior/health initiative Identify scientific questions Identify research areas of redundancy and areas that need to be developed Identify technology or infrastructure that needs to be developed Optimize chances for integrating efforts across research centers.
The matrix includes projects in laboratory animals and implicitly addresses development and gender. . proteins and their complexes. behavior individual and social.Social Network Matrix is based on a systems approach including data from all levels of biology: genes. circuits. cell.
Scientific Question SOCIAL NETWORKS BEHAVIOR CIRCUITS/ PATHWAYS CELL PROTEIN GENE 2.BRAIN BEHAVIOR & HEALTH ROAD MAP 1. Need for Technology . Infrastructure & Projects 3.
PAs and RFA With Other NIH Components PAs National Cooperative Drug Discovery Groups for the Treatment of Mood Disorders or Nicotine Addiction (NCDDG-MD/NA) Mechanisms of Alcoholic Pancreatitis Neurotechnology Research. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (F31) ELSI Regular Research Program (R01) ELSI Small Grant Research Program (R03) Transdisciplinary Tobacco Use Research Centers (with NCI and NIAAA) Group Therapy for Individuals in Drug Abuse or Alcoholism Treatment Screening and Intervention for Youth in Primary Care Settings HIV/AIDS. Drug Use and Highly Vulnerable Youth: Targeting Research Gaps (with NIMH) RFAs . Development and Enhancement Bioengineering Research Partnerships HIV/AIDS. Severe Mental Illness and Homelessness (with NIAAA and NIMH) Ruth L.
Percent of Students Reporting Any Illicit Drug Use in Past Year. by Grade 60 50 40 30 20 10 0 75 77 79 81 83 85 87 89 91 93 95 97 99 01 03 Monitoring the Future Study 2003 12th Grade 10th Grade 8th Grade .
M. Ph. – Deputy Chief. M.D.H.D. Special Assistant to the Deputy Director Susan Weiss.D. – Acting Head.P. – Prevention Research Branch Center on AIDS and Other Medical Consequences of Drug Abuse Center for the Clinical Trials Network Theresa Montini. M.Acting Chief. Ph. Ph.. Ph. – Deputy Chief. – Epidemiology Research Branch Elizabeth Genexi.D. Science Policy Branch Gayathri Jeyarasasingam – Science Policy Branch Mark Green.D. – Medications Research Grants Branch Jennifer Wong. Epidemiology Research Branch Yonette Thomas. – Regulatory Affairs Branch . Ph. Ph.D. – Deputy Director Division of Epidemiology. Science Policy Branch Robin Mackar. Services and Prevention Research Division of Treatment Research & Development Arnold Mills -.D.Recent NIDA Staff Appointments/Changes Office of the Director Office of Science Policy and Communication Office of Extramural Affairs Cheryl Kassed.. Medical Consequences Unit Denise Burns Steve Oversby.. Ph.D.H. -.D. M.D. – Chief.S. Special Assistant to the Director Helen Cesari. Ph. Jag H. Quinones. Epidemiology Research Branch Jessica Campbell. Arnaldo R. Epidemiology Research Branch Kevin Conway.P. Khalsa.S.D. Ph. Ph.D.Deputy Chief. Psy.
NIH NCI NIAAA NIA NIAMS NIBIB NIAID NIDCD NIDCR CIT NIDDK NIEHS NEI NHLBI CSR NIDA NIGMS NIMH NINR CC NCRR NCCAM NCMHD NICHD NHGRI FIC NINDS NLM .
chair Dr. DNBR. Susan Volman. Yu Lin and Nancy Pilotte. Robert Riddle. chair Embryogenesis of Reward-Based Behavior Dr. DNBR. Susan Volman and Pushpa Thadani. DNBR. David Shurtleff. chair . DNBR. DNBR. chair Dr. chair Neurobiological Mechanisms of Drug & Natural Reward Cognition &Behavior:Functional Changes in Synaptic Transmission & Drug Abuse Synaptic Transmission and Excitability: Genetically Encoded Biosensors for Defining Neuronal Circuits and Synaptic Change Dr. chair Young Investigators: Research & Funding Opportunities at NIDA Drs. Christine Colvis.NIDA-Sponsored Mini-Convention Endocannabinoids in the Brain: From Micro to Macro Drs. DNBR. DNBR. Jonathan Pollock. co-chairs Mechanisms of Receptor & Transporter Trafficking Dr. DNBR. co-chairs Signal Transduction Mechanism in Drug Abuse & Addiction Dr. Paul Schnur.
This action might not be possible to undo. Are you sure you want to continue?